Research: BOUZIANAS and COLLEAGUES,

Listed in Issue 240

Abstract

BOUZIANAS and COLLEAGUES,  (1)First Propedeutic Department of Internal Medicine, Medical School, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Macedonia, Greece reviewed PubMed literature and the ClinicalTrials.gov database to study the effects of omega-3 PUFA treatment upon non-alcoholic fatty liver disease (NAFLD).

Background

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in the Western world. Its prevalence has increased with the growing obesity epidemic, yet no definitive treatment has been developed, and optimal management remains a clinical challenge.

Methodology

Long-chain omega-3 polyunsaturated fatty acids (PUFAs) have recently been proposed as a potential treatment for liver inflammation associated with fat accumulation. PubMed literature and the ClinicalTrials.gov database were reviewed for the effects of omega-3 PUFA treatment on NAFLD, from mechanisms to the results of preclinical studies, human studies, and unreported ongoing clinical trials, using terms such as NAFLD, nonalcoholic steatohepatitis, omega-3 fatty acids, and fish oil.

Results

Articles published over the last 3-4 years were emphasized, and relevancy was ensured by scanning their abstracts.

Conclusion

Preliminary studies have confirmed an ameliorative effect, yet the translation of promising early data into therapeutic interventions will have to await the results of larger, properly conducted, ongoing clinical trials.

References

Bouzianas DG(1), Bouziana SD, Hatzitolios AI. Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. Nutr Rev. 71(11):753-71. Nov 2013. doi: 10.1111/nure.12073. Epub Oct 22 2013.

Munro Hall Clinic 2019

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Cycle India 2020

Walk on the Wide Side Trek Kenya 2020

Big Heart Bike Ride South Africa 2020

top of the page